Challenges in estimating the effectiveness of 2 doses of Covid-19 vaccine beyond 6 months in England
ORCID
- Wei, Yinghui: 0000-0002-7873-0009
Abstract
Understanding how the effectiveness of coronavirus disease 2019 (COVID-19) vaccine changes over time and in response to new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants is crucial to scheduling subsequent doses. In a previous study, Horne et al. (1) quantified vaccine effectiveness (VE) over 6 consecutive 4-week periods from 2 weeks to 26 weeks after the second dose. Waning of hazard ratios (HRs) when comparing vaccinated persons with unvaccinated persons was approximately log-linear over time and was consistent across COVID-19– related outcomes and risk-based subgroups. To investigate waning beyond 26 weeks and in the era of the Omicron variant, we extended follow-up to the earliest of 50 weeks after the second dose or March 31, 2022.
DOI
10.1093/aje/kwad179
Publication Date
2023-09-01
Publication Title
American Journal of Epidemiology
ISSN
0002-9262
Embargo Period
2023-12-07
Organisational Unit
School of Engineering, Computing and Mathematics
Recommended Citation
Horne, E. M., Hulme, W., Keogh, R., Palmer, T., Williamson, E., Parker, E., Walker, V., Knight, R., Wei, Y., Taylor, K., Fisher, L., Morley, J., Mehrkar, A., Dillingham, I., Bacon, S., Goldacre, B., & Sterne, J. (2023) 'Challenges in estimating the effectiveness of 2 doses of Covid-19 vaccine beyond 6 months in England', American Journal of Epidemiology, . Available at: https://doi.org/10.1093/aje/kwad179
